Research report · Public share

信达生物

HK · 01801 · 2026-10-22 · Full research
Cautiously bullish
Investment opportunity未来18个月风险回报温和偏正、非深度低估:2026H1产品收入+56.7%与三大全球化资产注册兑现构成基本盘,现价89.1港元较SOTP中枢98.4折让约10.4%、较基准下沿93仅约+4.4%——折让已基本定价指引路径兑现,是国谈与竞品两项未决风险的补偿而非免费期权,凸性主要来自IBI363等管线期权;验证窗口在未来六周的ESMO、Q3收入快报与11月国谈三连事件,破局观察首推玛仕度肽价格锚下修与竞争分流(R1)。
How was this report? Leave anonymous feedback.
This report was generated automatically by Loyan AI. For research reference only — not investment advice.
Want a research assistant that never forgets and challenges its own views?
Sign in to add this research to your library, or register for free to get started.
Sign in / register free